Search bioRxiv⌕ Search

Biology subjects

Go, S.-R.

Publications and source records attributed to Go, S.-R..

2 recordsLinked to original sources

AI-guided Protein Inhibitor Design for Modulating FAD-dependent Glucose Dehydrogenase Redox Output

Flavin adenine dinucleotide-dependent glucose dehydrogenase (FAD-GDH) is a redox enzyme widely used in glucose monitoring, bioelectronic devices, and enzymatic biofuel cells because of its oxygen-independent catalysis and compatibility with electron-transfer processes. However, protein-based regulators that directly bind GDH and modulate its redox output remain underdeveloped. Here, we present an AI-guided strategy for developing a de novo protein inhibitor targeting FAD-GDH. GDH-targeting candidates generated through structure-based computational design were evaluated by yeast surface display and fluorescence-activated cell sorting, leading to the identification of FAD-GDH inhibitor-1 (FGI-1) as a GDH-targeting inhibitory scaffold. Purified His-MBP-FGI-1 reduced GDH-mediated DCIP reduction, demonstrating attenuation of GDH-derived redox output. Random mutagenesis followed by secondary FACS screening yielded evolved variants with increased GDH-binding signals and enhanced redox-output suppression, showing that the de novo inhibitory scaffold could be functionally tuned through experimental evolution. In addition, an FGI-1-based construct fused to a larger protein module retained GDH-output suppressive activity, and electrode-based measurements showed reduced GDH-derived current output. Because electrode-associated measurements may be influenced by protein-mediated surface shielding and altered electron-transfer accessibility, this decrease was interpreted conservatively as attenuation of GDH-derived electrochemical output rather than direct evidence of active-site inhibition. Together, this work establishes an AI-guided design-validation workflow for developing protein inhibitors that modulate FAD-GDH redox output and provides a foundation for protein-level control of enzyme output in biosensing and bioelectronic applications.

biochemistry↗

AI-Driven Design of Nanobinders Targeting the TSLPR Heterodimer Interface to Suppress Type 2 Inflammatory Signaling

Aberrant thymic stromal lymphopoietin (TSLP) signaling is a central driver of type 2 inflammatory diseases, yet the only approved TSLP-targeted therapy is a 150 kDa monoclonal antibody whose bulky format limits tissue penetration and precludes inhaled delivery. Here, we report an AI-driven framework for designing ultra-compact de novo nanobinders that suppress TSLP signaling by sterically disrupting assembly of the TSLPR-IL-7R heterodimer. We compare two structure-guided strategies, namely purely de novo helical bundle generation and interface-mimetic grafting of native binding motifs onto designed scaffolds. Although both yield nanomolar binders, only orthosteric mimicry of the native cytokine geometry blocks receptor heterodimerization, showing that functional antagonism is governed by precise epitope geometry rather than affinity alone. After library-based maturation, the lead nanobinder TRB5.1 is a hyper-stable monomer (Tm [~]97.4 {degrees}C) with single-digit nanomolar affinity (KD = 9.7 nM) and strict selectivity over related -chain interleukin receptors. TRB5.1 suppresses TSLP-induced JAK1 and STAT5 phosphorylation across multiple cellular models and drives a transcriptome-wide reversal of the pathogenic type 2 program. This work delivers a developable, potentially inhalable non-antibody lead and a scalable blueprint for antagonizing heterodimeric cytokine receptors.

biochemistry↗